The type 1 NKT cell stimulating glycolipid α-galactosylceramide (α-GalCer) was first identified by the Pharmaceutical Research Laboratory of Kirin Brewery in a screen for novel anti-tumor agents. Based on promising preclinical data it was tested as an anticancer drug in multiple clinical studies.
Better understanding of AML biology and survival tactics has facilitated a wave of newly approved drugs against AML and also revealed a range of targets to be exploited for treatment. In our review, we discuss what these new targets are and how targeting them in combination might be beneficial.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomized clinical trial
Horizontal propagation of EMT, stemness, and metastasis by transferring the MAP17 protein through secreted vesicles
José Manuel García-Heredia, Daniel Otero-Albiol, Marco Pérez, Elena Pérez-Castejón, Sandra Muñoz-Galván and Amancio Carnero; Instituto de Biomedicina de Sevilla (IBIS/HUVR/Universidad de Sevilla/CSIC); CIBERONC